Alto Neuroscience Secures $120M in Private Placement to Advance CNS Pipeline
Alto Neuroscience has successfully raised $120 million through a private placement, a significant capital injection aimed at accelerating its precision psychiatry platform. Led by CFO Nick Smith, the financing highlights growing investor confidence in biomarker-driven approaches to treating central nervous system (CNS) disorders.